Publicaciones en las que colabora con Maria Angeles Muñoz Fernandez (178)

2024

  1. Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain

    AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314

  2. Changes in bodyweight after initiating antiretroviral therapy close to HIV-1 seroconversion: an international cohort collaboration

    The Lancet HIV, Vol. 11, Núm. 10, pp. e660-e669

  3. IgG antibody levels against the SARS-CoV-2 spike protein in mother–child dyads after COVID-19 vaccination

    Infection, Vol. 52, Núm. 3, pp. 813-824

  4. Low unspliced cell-associated HIV RNA in early treated adolescents living with HIV on long suppressive ART

    Frontiers in Immunology, Vol. 15

2023

  1. Antibody levels to SARS-CoV-2 spike protein in mothers and children from delivery to six months later

    Birth, Vol. 50, Núm. 2, pp. 418-427

  2. Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial

    The Lancet Child and Adolescent Health, Vol. 7, Núm. 10, pp. 718-727

  3. Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV – Week 48 results of the randomised SMILE Penta-17-ANRS 152 clinical trial

    eClinicalMedicine, Vol. 60

2022

  1. Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

    The Lancet HIV, Vol. 9, Núm. 9, pp. e627-e637

  2. Impact of Gestational COVID-19 on Neonatal Outcomes: Is Vertical Infection Possible?

    The Pediatric infectious disease journal, Vol. 41, Núm. 6, pp. 466-472

  3. Nutritional Supplementation to Increase Influenza Vaccine Response in Children Living With HIV: A Pilot Clinical Trial

    Frontiers in Pediatrics, Vol. 10

  4. Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial

    The Lancet HIV, Vol. 9, Núm. 9, pp. e638-e648

  5. Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort

    HIV Medicine, Vol. 23, Núm. 8, pp. 825-836

  6. Risk-score based strategy to minimize antibiotic exposure in children with sickle cell disease and fever

    Infection, Vol. 50, Núm. 2, pp. 499-505

  7. Targeting the Gut Microbiota of Vertically HIV-Infected Children to Decrease Inflammation and Immunoactivation: A Pilot Clinical Trial

    Nutrients, Vol. 14, Núm. 5

  8. Vaginal neutrophil infiltration is contingent on ovarian cycle phase and independent of pathogen infection

    Frontiers in Immunology, Vol. 13

2021

  1. COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study

    HIV Medicine, Vol. 22, Núm. 9, pp. 867-876

  2. Innate and adaptive abnormalities in youth with vertically acquired HIV through a multicentre cohort in Spain

    Journal of the International AIDS Society, Vol. 24, Núm. 10

  3. Interleukin 6 as a marker of severe bacterial infection in children with sickle cell disease and fever: a case–control study

    BMC Infectious Diseases, Vol. 21, Núm. 1

  4. Longitudinal plasma cytokine concentrations and recurrent wheezing after RSV bronchiolitis

    Cytokine, Vol. 140

  5. Role of G2-S16 polyanionic carbosilane dendrimer in the prevention of respiratory syncytial virus infection in vitro and in vivo in mice

    Polymers, Vol. 13, Núm. 13